Prolonged Apnea Following Succinylcholine in Cancer Patients Receiving AB-132

Abstract
Prolonged apnea was attributable to the inhibition of the plasma and red blood cell cholinesterases by a antitumor agent, AB-132, which was given to the patients prior to operation. The marked inhibitory effects of AB-132 on blood cholinesterase were demonstrated both in vitro and in four other cancer patients on AB-132 therapy. It is concluded that succinylcholine should not be given during anesthesia to patients receiving this cancer chemotherapeutic agent.

This publication has 0 references indexed in Scilit: